Liver Cancer最新文献

{"title":"¹⁸F-FDG PET/CT Predicts the Prognosis of Patients with Hepatocellular Carcinoma Undergoing Liver Transplantation.","authors":"Wen-Jing Zheng, Yang Xu, Hui Tan, Shu-Guang Chen, Peng-Xiang Wang, Hai-Xiang Sun, Rui-Zhe Li, Hai-Ying Zeng, Yu-Chen Zhong, Jian-Wen Cheng, Jia Fan, Jian Zhou, Hongcheng Shi, Xin-Rong Yang","doi":"10.1159/000544966","DOIUrl":"https://doi.org/10.1159/000544966","url":null,"abstract":"<p><strong>Introduction: </strong>In addition to radical resection, liver transplantation (LTx) is an effective treatment for hepatocellular carcinoma (HCC). However, tumor recurrence limits the efficacy of LTx in some patients. This study investigated the role of ¹⁸F-fludeoxyglucose (¹⁸F-FDG) positron emission tomography/computed tomography (PET/CT) in predicting the prognosis of patients with HCC after LTx.</p><p><strong>Methods: </strong>A total of 278 consecutive patients with HCC who underwent pre-LTx PET/CT were divided into derivation (<i>n</i> = 178) and temporal validation (<i>n</i> = 100) cohorts and evaluated for PET/CT values, immunohistochemical (IHC) findings, and DNA sequencing of tumor tissues.</p><p><strong>Results: </strong>Patients with post-LTx recurrence exhibited significantly higher tumor maximum standardized uptake values (SUVmax) in pre-LTx PET/CT scans. Receiver operating characteristic curve analyses identified the tumor SUVmax to liver SUVmax ratio (T_SUVmax/L_SUVmax) as the strongest predictor of post-LTx recurrence, with an optimal cutoff value of 1.43. Kaplan-Meier analyses demonstrated that a T_SUVmax/L_SUVmax >1.43 was associated with a shorter time to recurrence (TTR) and overall survival (OS) in both cohorts (<i>p</i> < 0.001 for both). Multivariate Cox regression analyses confirmed that T_SUVmax/L_SUVmax >1.43 was an independent risk factor for tumor recurrence in both cohorts. IHC revealed that T_SUVmax/L_SUVmax >1.43 correlated with higher Ki-67 and CK19 expression. DNA sequencing indicated that tumors with T_SUVmax/L_SUVmax >1.43 had more mutations and a higher TMB. Furthermore, T_SUVmax/L_SUVmax >1.43 was significantly associated with mutations in <i>TP53</i>, <i>EPPK1</i>, <i>MDM4</i>, <i>SLAMF7</i>, <i>SDHC</i>, <i>B4GALT3</i>, <i>RXRG</i>, and FCGR family genes, as well as TP53 and PI3K signaling-related alterations.</p><p><strong>Conclusions: </strong>The preoperative T_SUVmax/L_SUVmax is a potential predictor of tumor recurrence in patients with HCC following LTx. Its use improves candidate selection and post-LTx management.</p>","PeriodicalId":18156,"journal":{"name":"Liver Cancer","volume":" ","pages":"1-21"},"PeriodicalIF":11.6,"publicationDate":"2025-03-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11998673/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143971519","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Depth and Duration of Response Are Associated with Survival in Patients with Unresectable Hepatocellular Carcinoma: Exploratory Analyses of IMbrave150.","authors":"Masatoshi Kudo, Tatsuya Yamashita, Richard S Finn, Peter R Galle, Michel Ducreux, Ann-Lii Cheng, Kaoru Tsuchiya, Naoya Sakamoto, Shuhei Hige, Ryosuke Take, Kyoko Yamada, Yuki Nakagawa, Hayato Takahashi, Masafumi Ikeda","doi":"10.1159/000544981","DOIUrl":"https://doi.org/10.1159/000544981","url":null,"abstract":"<p><strong>Introduction: </strong>IMbrave150 established first-line atezolizumab plus bevacizumab as a global standard of care for unresectable hepatocellular carcinoma (HCC). We report exploratory analyses of associations between overall survival (OS) and depth of response (DpR) or duration of response (DoR).</p><p><strong>Methods: </strong>IMbrave150 was a phase III randomized study of atezolizumab plus bevacizumab versus sorafenib in patients with unresectable HCC. DpR was defined as maximum tumor shrinkage from baseline based on the sum of longest diameters per independent review facility (IRF)-assessed RECIST 1.1. DoR was defined as time from first complete/partial response by IRF-assessed RECIST 1.1 until progression or death. Associations between OS and DpR or DoR were evaluated by scatterplot in both arms; OS and PFS were evaluated by DpR in atezolizumab plus bevacizumab-treated patients. To minimize immortal time bias, the DpR analysis included patients who survived ≥6 months.</p><p><strong>Results: </strong>Of 312 and 140 patients with baseline measurable disease in the atezolizumab plus bevacizumab and sorafenib arms, respectively, 264 and 99 surviving ≥6 months were included in the DpR analysis, and 97 and 18 in the DoR analysis. Tumor shrinkage occurred in 230/312 (74%) patients in the atezolizumab plus bevacizumab arm and 76/140 (54%) in the sorafenib arm; their mean (SD) DpR was -42.5% (32.4%) and -25.0% (21.9%), respectively. Atezolizumab plus bevacizumab-treated ≥6-month survivors with DpR <0% had improved OS versus those with DpR ≥0% (HR: 0.29; 95% CI: 0.19-0.44). Those with deeper responses (DpR -100% to -60%) had longer OS than those with DpR ≥20% (unstratified HR: 0.08; 95% CI: 0.03-0.21). In scatterplots, DpR and DoR were generally associated with OS in both arms; interpretation was limited by censored patients.</p><p><strong>Conclusions: </strong>DpR and DoR to atezolizumab plus bevacizumab and sorafenib were associated with OS in patients with unresectable HCC. More longer, deeper responses occurred with atezolizumab plus bevacizumab.</p>","PeriodicalId":18156,"journal":{"name":"Liver Cancer","volume":" ","pages":"1-16"},"PeriodicalIF":11.6,"publicationDate":"2025-03-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12052357/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144032339","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Asian Conference on Tumor Ablation Guidelines for Hepatocellular Carcinoma.","authors":"Shuichiro Shiina, Ryosuke Tateishi, Joon Il Choi, So Yeon Kim, Zhiqiang Meng, Lujun Shen, Sheng-Nan Lu, Jen-I Hwang, Maki Tobari, Hitoshi Maruyama, Terguunbileg Batsaikhan, Qing Deng, Lariza Marie Canseco, Yoshinari Asaoka, Shi-Ming Lin, Kai-Wen Huang, Hyunchul Rhim, Ping Liang, Uei Pua, Masatoshi Tanaka, Peihong Wu","doi":"10.1159/000544976","DOIUrl":"https://doi.org/10.1159/000544976","url":null,"abstract":"<p><p>Globally, the incidence and associated mortality of primary liver cancer have been steadily increasing. Currently, 80% of cases are found in Asia. Curative resection is applicable in only 20% of patients; therefore, various nonsurgical treatment modalities have been developed. Image-guided percutaneous liver tumor ablation is regarded as the best option for treating early-stage hepatocellular carcinoma (HCC). However, skills and knowledge in ablation can vary among operators. Furthermore, Asia has the highest number of ablation procedures for HCC and the largest number of doctors performing ablation worldwide. Thus, the Asian Conference on Tumor Ablation has developed guidelines for HCC. These guidelines will discuss indications, pre-ablative diagnosis and planning, techniques, peri-ablative management, evaluation of therapeutic effectiveness, complications, post-ablative follow-up, prevention of recurrence, and treatment of recurrence for HCC.</p>","PeriodicalId":18156,"journal":{"name":"Liver Cancer","volume":" ","pages":"1-27"},"PeriodicalIF":11.6,"publicationDate":"2025-03-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11998674/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144016030","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Erratum.","authors":"","doi":"10.1159/000543481","DOIUrl":"https://doi.org/10.1159/000543481","url":null,"abstract":"<p><p>[This corrects the article DOI: 10.1159/000528034.].</p>","PeriodicalId":18156,"journal":{"name":"Liver Cancer","volume":"14 3","pages":"353"},"PeriodicalIF":11.6,"publicationDate":"2025-02-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12182755/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144475841","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Lenvatinib plus Pembrolizumab Combined with Transarterial Chemoembolization in Intermediate-Stage Hepatocellular Carcinoma.","authors":"Masatoshi Kudo","doi":"10.1159/000543245","DOIUrl":"10.1159/000543245","url":null,"abstract":"","PeriodicalId":18156,"journal":{"name":"Liver Cancer","volume":"14 1","pages":"1-7"},"PeriodicalIF":11.6,"publicationDate":"2024-12-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11936454/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143719865","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comprehensive Analysis of Radiologic Cancer-Free Status through Various Treatment Approaches in Advanced-Stage Hepatocellular Carcinoma.","authors":"Keisuke Koroki, Sadahisa Ogasawara, Ryo Izai, Takuya Yonemoto, Teppei Akatsuka, Chihiro Miwa, Sae Yumita, Masanori Inoue, Kazufumi Kobayashi, Soichiro Kiyono, Masato Nakamura, Naoya Kanogawa, Takayuki Kondo, Shingo Nakamoto, Shinichiro Nakada, Nozomu Sakai, Masayuki Yokoyama, Masayuki Ohtsuka, Naoya Kato","doi":"10.1159/000542577","DOIUrl":"10.1159/000542577","url":null,"abstract":"<p><strong>Introduction: </strong>In the realm of oncology, the pinnacle of therapeutic success is achieving a state where the patient is entirely free of cancer, i.e., \"cancer free.\" This benchmark should not only apply to early-stage malignancies but should also be the standard aim for advanced-stage diseases, including hepatocellular carcinoma (HCC). However, there is a glaring gap in the research landscape concerning the understanding of what cancer-free status truly means for advanced-stage HCC. Our study sheds light on the profound implications of reaching a cancer-free by radiologic assessments in patients with advanced-stage HCC.</p><p><strong>Methods: </strong>We established a database tracking the full clinical course of all patients with HCC (from 2003 to 2022). We identified the initial instances of macrovascular invasion or extrahepatic spread. We defined radiologic cancer-free (rCF) as cases in which no recurrence was observed for at least 2 months following curative treatment or complete response to systemic therapies. The frequency of achieving rCF status was investigated, categorized by patients' background.</p><p><strong>Results: </strong>We identified 795 patients with advanced-stage HCC. The rCF rate was 8.7%. Patients who achieved rCF status had significantly better prognoses compared to those who did not (<i>p</i> < 0.001). In the decision tree analysis, the number of tumors ≥8 was the strongest factor, making it difficult to achieve rCF status. Analysis of stage progression patterns revealed varying background characteristics at the time of advanced-stage diagnosis, with discrepancies in rCF rates.</p><p><strong>Conclusions: </strong>Despite the low rate of achieving rCF status, the prognostic impact was significant. Patients with certain tumor characteristics had a higher likelihood of achieving rCF status. The distribution of tumor conditions varies based on the pattern of progression, which affects the likelihood of achieving an rCF status.</p>","PeriodicalId":18156,"journal":{"name":"Liver Cancer","volume":"14 3","pages":"286-301"},"PeriodicalIF":11.6,"publicationDate":"2024-11-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12180894/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144475839","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Demographics and Immunotherapy Efficacy for Advanced Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis of Phase III Clinical Trials.","authors":"Yu-Yun Shao, Andrei R Akhmetzhanov","doi":"10.1159/000542576","DOIUrl":"10.1159/000542576","url":null,"abstract":"<p><strong>Introduction: </strong>Immune checkpoint inhibitors (ICIs) are fundamental in treating advanced hepatocellular carcinoma (HCC). Considering previous reports implied varied responses among patient subgroups, such as patients with different hepatitis etiologies, we planned this meta-analysis to identify specific populations that might derive greater survival benefits from ICIs as a first-line treatment.</p><p><strong>Methods: </strong>We conducted a comprehensive search in PubMed and the Cochrane Library for phase III clinical trials comparing ICIs and multikinase inhibitors (MKIs) as first-line therapies for advanced HCC. We extracted and synthesized hazard ratios (HRs) for overall survival across different patient subgroups mainly using the random-effect model.</p><p><strong>Results: </strong>Our analysis included nine phase III trials involving ICIs, either alone or in combination with other treatments, compared with MKIs. The synthesized HRs for patients with hepatitis B virus, hepatitis C virus, and nonviral etiologies were 0.74, 0.77, and 0.86, respectively, showing no significant differences (<i>p</i> = 0.13). Such finding remained when we only analyzed clinical trials with positive results. HRs consistently favored ICIs across various demographics such as age, sex, geographic region, performance status, alpha-fetoprotein levels, and disease stage or extent. Notably, patients with extrahepatic spread showed a trend toward better outcomes (HR 0.73) compared to those without (HR 0.85, <i>p</i> = 0.07).</p><p><strong>Conclusion: </strong>The efficacy of ICIs as a first-line treatment for advanced HCC was consistent across diverse patient subgroups, regardless of hepatitis etiology or other demographic factors. These findings do not support using these characteristics to determine the use of ICI therapy in advanced HCC.</p>","PeriodicalId":18156,"journal":{"name":"Liver Cancer","volume":"14 3","pages":"302-310"},"PeriodicalIF":11.6,"publicationDate":"2024-11-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12180893/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144475840","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Gadoxetic Acid-Enhanced Magnetic Resonance Imaging Features Can Predict Immune-Excluded Phenotype of Hepatocellular Carcinoma.","authors":"Eisuke Ueshima, Keitaro Sofue, Takahiro Kodama, Shuhei Yamamoto, Masato Komatsu, Shohei Komatsu, Nobuaki Ishihara, Akihiro Umeno, Takeru Yamaguchi, Masatoshi Hori, Takumi Fukumoto, Tetsuo Takehara, Takamichi Murakami","doi":"10.1159/000542099","DOIUrl":"10.1159/000542099","url":null,"abstract":"<p><strong>Introduction: </strong>Immunotherapy is the first-line treatment for intermediate-advanced stage hepatocellular carcinoma (HCC), although its outcomes vary. This study aimed to identify imaging biomarkers of immunotherapy susceptibility linked to gadoxetic acid-enhanced magnetic resonance imaging (EOB-MRI) and immune phenotypes, particularly immune-excluded phenotypes, with a tumor immune barrier.</p><p><strong>Methods: </strong>We performed immunohistochemical staining with a CD8⁺ antibody, and samples were classified into immune-inflamed, -intermediate, -excluded, and -ignored phenotypes. We assessed EOB-MRI findings obtained from 104 patients who underwent hepatectomy for HCC and evaluated the relationship between MRI findings and immune phenotype. Spatial transcriptome analysis of tumor tissues in each immune phenotype was performed to characterize the MRI findings. For validation, we analyzed the treatment effect on 60 nodules in another cohort of 27 patients who received combined immunotherapy using anti-programmed death-ligand 1 and anti-vascular endothelial growth factor (VEGF) antibodies.</p><p><strong>Results: </strong>HCCs with rim arterial phase hyperenhancement (APHE) (odds ratio [OR] 17.3, <i>p</i> = 0.009), peritumoral enhancement in the arterial phase (OR: 8.6, <i>p</i> < 0.004), and intermediate intensity on the hepatobiliary phase (HBP) measured with a visual 3-point scale (OR: 28.2, <i>p</i> = 0.002) were associated with immune-excluded phenotype, where tumors tended to be larger and of the single nodular type with extranodular growth and confluent multinodular rather than the simple nodular type. Spatial transcriptome analysis revealed a spatial relationship among cytotoxic T lymphocytes, VEGF signals, and cancer-associated fibroblasts at the tumor-invasive margins in this phenotype. From the validation study, nodules with any one of these three imaging findings had a significantly prolonged time to-nodular progression (<i>p</i> = 0.007, median not reached vs. 226 days).</p><p><strong>Conclusion: </strong>HCCs with rim APHE, peritumoral enhancement in arterial phase, and intermediate intensity on HBP with visual 3-point scale could be non-invasive biomarkers to predict the immune-excluded phenotype with the tumor immune barrier. These HCCs were most likely to respond to combined immunotherapy.</p>","PeriodicalId":18156,"journal":{"name":"Liver Cancer","volume":"14 3","pages":"271-285"},"PeriodicalIF":11.6,"publicationDate":"2024-11-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12180895/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144475842","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Challenges in Adjuvant Immunotherapy after Resection or Ablation for Hepatocellular Carcinoma at High-Risk of Recurrence.","authors":"Masatoshi Kudo","doi":"10.1159/000542221","DOIUrl":"10.1159/000542221","url":null,"abstract":"","PeriodicalId":18156,"journal":{"name":"Liver Cancer","volume":"13 6","pages":"573-578"},"PeriodicalIF":11.6,"publicationDate":"2024-10-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11649295/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142837140","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Chinese Expert Consensus on the Whole-Course Management of Hepatocellular Carcinoma (2023 Edition).","authors":"Yu Yang, Juxian Sun, Jianqiang Cai, Minshan Chen, Chaoliu Dai, Tianfu Wen, Jinglin Xia, Mingang Ying, Zhiwei Zhang, Xuewen Zhang, Chihua Fang, Feng Shen, Ping An, Qingxian Cai, Jingyu Cao, Zhen Zeng, Gang Chen, Juan Chen, Ping Chen, Yongshun Chen, Yunfeng Shan, Shuangsuo Dang, Wei-Xing Guo, Jiefeng He, Heping Hu, Bin Huang, Weidong Jia, Kexiang Jiang, Yan Jin, Yongdong Jin, Yun Jin, Gong Li, Yun Liang, Enyu Liu, Hao Liu, Wei Peng, Zhenwei Peng, Zhiyi Peng, Yeben Qian, Wanhua Ren, Jie Shi, Yusheng Song, Min Tao, Jun Tie, Xueying Wan, Bin Wang, Jin Wang, Kai Wang, Kang Wang, Xin Wang, Wenjing Wei, Fei-Xiang Wu, Bangde Xiang, Lin Xie, Jianming Xu, Mao-Lin Yan, Yufu Ye, Jinbo Yue, Xiaoxun Zhang, Yu Zhang, Aibin Zhang, Haitao Zhao, Weifeng Zhao, Xin Zheng, Hongkun Zhou, Huabang Zhou, Jun Zhou, Xinmin Zhou, Shu-Qun Cheng, Qiu Li","doi":"10.1159/000541622","DOIUrl":"10.1159/000541622","url":null,"abstract":"<p><strong>Background: </strong>Hepatocellular carcinoma (HCC) is one of the most common malignant tumors in China. Most HCC patients have the complications of chronic liver disease and need overall consideration and whole-course management, including diagnosis, treatment, and follow-up. To develop a reasonable, long-term, and complete management plan, multiple factors need to be considered, including the patient's general condition, basic liver diseases, tumor stage, tumor biological characteristics, treatment requirements, and economic cost.</p><p><strong>Summary: </strong>To better guide the whole-course management of HCC patients, the Chinese Association of Liver Cancer and the Chinese Medical Doctor Association has gathered multidisciplinary experts and scholars in relevant fields to formulate the \"Chinese Expert Consensus on The Whole-Course Management of Hepatocellular Carcinoma (2023).\"</p><p><strong>Key messages: </strong>This expert consensus, based on the current clinical evidence and experience, proposes surgical and nonsurgical HCC management pathways and involves 18 recommendations, including perioperative treatment, systematic treatment combined with local treatment, conversion treatment, special population management, symptomatic support treatment, and follow-up management.</p>","PeriodicalId":18156,"journal":{"name":"Liver Cancer","volume":"14 3","pages":"311-333"},"PeriodicalIF":11.6,"publicationDate":"2024-10-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12180802/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144475838","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}